Charles River Labs Files 8-K Amendment on Officer/Director Changes
Ticker: CRL · Form: 8-K/A · Filed: Sep 19, 2025 · CIK: 1100682
| Field | Detail |
|---|---|
| Company | Charles River Laboratories International, INC. (CRL) |
| Form Type | 8-K/A |
| Filed Date | Sep 19, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $500,000, $10,000 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, amendment, compensation
Related Tickers: CRL
TL;DR
CRL filed an 8-K/A on 9/19 for 9/12 events: director/officer changes & comp. Watch for leadership shifts.
AI Summary
Charles River Laboratories International, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on September 19, 2025, related to events occurring on September 12, 2025. The filing concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers.
Why It Matters
This amendment provides updated information regarding significant changes in the company's leadership and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially if unexpected, can signal internal shifts or strategic realignments that may affect the company's future performance.
Key Players & Entities
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (company) — Registrant
- 0000950103-25-011896 (filing_id) — Accession Number
- September 19, 2025 (date) — Filing Date
- September 12, 2025 (date) — Date of Earliest Event Reported
FAQ
What specific event triggered this 8-K/A filing?
This is an amendment to a previous 8-K filing, specifically Amendment No. 1, filed on September 19, 2025, concerning events that occurred on September 12, 2025.
What are the main topics covered in this amendment?
The amendment covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the exact name of the company filing this report?
The exact name of the registrant is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
On what date was this amendment filed with the SEC?
This amendment was filed as of September 19, 2025.
What is the Commission File Number for this filing?
The Commission File Number is 001-15943.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-09-19 16:14:24
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value CRL New York Stock Exchange
- $500,000 — i) an increase in annual base salary to $500,000, effective September 28, 2025; (ii) a $
- $10,000 m — 0, effective September 28, 2025; (ii) a $10,000 monthly cash payment to be paid during Mr
Filing Documents
- dp234578_8ka-1.htm (8-K/A) — 22KB
- 0000950103-25-011896.txt ( ) — 183KB
- crl-20250912.xsd (EX-101.SCH) — 3KB
- crl-20250912_lab.xml (EX-101.LAB) — 33KB
- crl-20250912_pre.xml (EX-101.PRE) — 22KB
- dp234578_8ka-1_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On September 16, 2025, Charles River Laboratories International, Inc. (the "Company") filed a current report on Form 8-K under item 5.02 to report the resignation of Flavia H. Pease as Corporate Executive Vice President, Chief Financial Officer of the Company and the appointment of Michael G. Knell as interim Chief Financial Officer of the Company. The Company is filing this Form 8-K/A to disclose details of Mr. Knell's compensation that were not determined at the time of the original filing. On September 15, 2025, in connection with Mr. Knell's appointment as interim Chief Financial Officer and interim principal financial officer of the Company, the Compensation Committee of the Company's Board of Directors approved the following changes to Mr. Knell's compensation package: (i) an increase in annual base salary to $500,000, effective September 28, 2025; (ii) a $10,000 monthly cash payment to be paid during Mr. Knell's term of service as interim Chief Financial Officer, effective October 1, 2025; and (iii) a one-time grant of restricted stock units of the Company's common stock with a grant value of $500,000, to be granted on November 6, 2025 (the first business day following the press release with respect to financial results for the third fiscal quarter of 2025), with 50% to vest on the first anniversary of the grant date and the remaining 50% to vest on the second anniversary of the grant date.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Date: September 19, 2025 By: /s/ Matthew L. Daniel Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer